Type 2 Diabetes

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Ozempic’s approval in a higher-dose oral form and lingering concerns over compounded drugs.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

Catch up with major trial results, key FDA approvals, and more.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review tech updates from Sequel Med Tech, Diabeloop, and Medtronic.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.

According to an announcement by parent company Medtronic, the MiniMed Go app is expected to launch in the spring of 2026.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

A recent retrospective cohort analysis of the ACCORD phase 3 study has revealed a correlation between higher index values and increased mortality risk.

Catch up on the most impactful headlines in T2D from all of 2025 with our Year in Review.

Explore the latest advancements in diabetes technology, including updates on CGMs and insulin pumps, enhancing patient care and management.

GLP-1 medications are revolutionizing treatment for neurological conditions.

Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.

Catch up with major trial results, key clinician insights, and more.

This special edition episode explores the advancements in incretin therapies that defined 2025.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

Discover the latest advancements in diabetes technology from November 2025, including Omnipod updates and the new Pivot pump.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.

This episode covers the upcoming release of Dexcom's G7 15-day patch and major price cuts for semaglutide.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.